New York, January 6, 2026, 12:36 PM ET — Regular session
- AbbVie shares up about 0.5% in midday trade after a near-4% drop on Monday
- Health Canada approved AbbVie’s Maviret for acute and chronic hepatitis C, the company said
- Focus turns to Jan. 14 J.P. Morgan Healthcare Conference and late-January earnings timing
AbbVie shares rose about 0.5% to $221.18 in midday trading on Tuesday after the drugmaker said Health Canada approved its hepatitis C therapy Maviret (glecaprevir/pibrentasvir) for acute and chronic infections.
The clearance expands use of an eight-week oral regimen and supports “treat early” strategies aimed at cutting transmission by starting therapy as soon as patients are diagnosed. That matters as investors look for steadier growth drivers and pipeline progress ahead of key investor events this month.
AbbVie said Maviret is now approved in Canada for adults and children aged 3 and older who weigh at least 12 kg, and is “pan-genotypic,” meaning it is designed to work across major hepatitis C virus (HCV) strains. “Early detection and treatment of acute hepatitis C is critical” to reaching global elimination goals, Dr. Brian Conway, medical director of the Vancouver Infectious Diseases Centre, said in the release. BioSpace
The Canada decision lands as AbbVie continues to add assets to its development pipeline. BioSpace reported on Monday that AbbVie agreed to pay $100 million upfront for an option to license ex-China rights to Zelgen’s ZG006 (alveltamig), a DLL3-targeting drug being studied in small cell lung cancer and positioned as a potential rival to Amgen’s Imdelltra.
AbbVie also said it will present at the J.P. Morgan Healthcare Conference on Jan. 14, with management scheduled for a fireside chat at 10:15 a.m. Central time.
The stock fell 3.98% to $220.18 in the previous session, underperforming peers such as Johnson & Johnson and Pfizer, and volume ran above its recent average, MarketWatch data showed. Shares are about 10% below their 52-week high of $244.81, leaving the $220 area in view for traders tracking near-term support.
The next major read-through is AbbVie’s quarterly report, which Nasdaq’s earnings calendar lists as an estimated Jan. 30 release. Investors will look for 2026 expectations and updates on key growth franchises, including immunology drugs Skyrizi and Rinvoq, alongside any read-through from recent business development.
But approvals outside the United States do not always translate into a meaningful earnings lift, and hepatitis C treatment volumes can swing as health systems work through diagnosed patient pools. New licensing deals also carry clinical and competitive risks, particularly in crowded oncology targets.
For now, attention turns to AbbVie’s Jan. 14 appearance at the J.P. Morgan conference, followed by its late-January results and outlook for 2026.
